Literature DB >> 33260128

Deep brain stimulation telemedicine programming during the COVID-19 pandemic: treatment of patients with psychiatric disorders.

Zhengyu Lin1,2, Chencheng Zhang1,2,3, Yingying Zhang1,2, Lulin Dai1,2, Valerie Voon4, Dianyou Li1,2, Bomin Sun1,2.   

Abstract

OBJECTIVE: The ongoing coronavirus disease 2019 (COVID-19) pandemic has considerably affected the delivery of postoperative care to patients who have undergone deep brain stimulation (DBS) surgery. DBS teleprogramming technology was developed and deployed in China before the COVID-19 outbreak. In this report, the authors share their experiences with telemedical DBS treatment of patients with psychiatric disorders during the COVID-19 outbreak.
METHODS: Four patients (2 with obsessive-compulsive disorder, 1 with major depressive disorder, and 1 with anorexia nervosa) underwent DBS surgery at Ruijin Hospital and received continuous postoperative DBS telemedicine case management from January 2020 to July 2020. DBS teleprogramming, individualized psychological support, and medical consultations were provided via the authors' DBS telemedicine platform, which also incorporated a synchronous real-time video communication system.
RESULTS: Forty-five DBS telemedicine sessions were conducted; there was no unexpected loss of network connection during the sessions. Of these, 28 sessions involved DBS teleprogramming. Adjustments were made to the stimulation voltage, frequency, pulse width, and contact site in 21, 12, 9, and 9 sessions, respectively. Psychological support and troubleshooting were provided during the remaining telemedicine sessions. Modest to substantial clinical improvements after DBS surgery were observed in some but not all patients, whereas stimulation-related side effects were reported by 2 patients and included reversible sleep and mood problems, headache, and a sensation of heat.
CONCLUSIONS: DBS telemedicine seems to offer a feasible, safe, and efficient strategy for maintaining the delivery of medical care to psychiatric patients during the COVID-19 outbreak. The authors propose that implementation of a comprehensive DBS telemedicine system, which combines DBS teleprogramming with psychological counseling, medical consultations, and medication prescriptions and delivery, could be an efficient and effective approach to manage the mental health and quality of life of patients with psychiatric disorders during future local or global public health crises.

Entities:  

Keywords:  COVID-19; case management; deep brain stimulation; psychiatric disorder

Mesh:

Year:  2020        PMID: 33260128     DOI: 10.3171/2020.9.FOCUS20666

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  5 in total

1.  Potential clinical and economic benefits of remote deep brain stimulation programming.

Authors:  Dávid Pintér; Evelyn Járdaházi; József Janszky; Norbert Kovács
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

2.  Deep Brain Stimulation for Parkinson's Disease During the COVID-19 Pandemic: Patient Perspective.

Authors:  Chencheng Zhang; Jing Zhang; Xian Qiu; Yingying Zhang; Zhengyu Lin; Peng Huang; Yixin Pan; Eric A Storch; Bomin Sun; Dianyou Li
Journal:  Front Hum Neurosci       Date:  2021-04-01       Impact factor: 3.169

Review 3.  Analysis of Factors Influencing Telemedicine-Based Psychiatric Extended Care and Care of Psychiatric Patients.

Authors:  Wenjian Xu; Guang Gu; Libo Dong; Lina Wang
Journal:  J Healthc Eng       Date:  2022-01-17       Impact factor: 2.682

Review 4.  Past, Present, and Future of Deep Brain Stimulation: Hardware, Software, Imaging, Physiology and Novel Approaches.

Authors:  Jessica Frey; Jackson Cagle; Kara A Johnson; Joshua K Wong; Justin D Hilliard; Christopher R Butson; Michael S Okun; Coralie de Hemptinne
Journal:  Front Neurol       Date:  2022-03-09       Impact factor: 4.003

Review 5.  Telemedicine in Surgical Care in Low- and Middle-Income Countries: A Scoping Review.

Authors:  Eyitayo Omolara Owolabi; Tamlyn Mac Quene; Johnelize Louw; Justine I Davies; Kathryn M Chu
Journal:  World J Surg       Date:  2022-04-15       Impact factor: 3.282

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.